Innovent Biologics (IVBXF) Financial Statements
54 Followers
Innovent Biologics Financial Overview
Innovent Biologics's market cap is currently ¥17.96B. The company's EPS TTM is ¥0.71; its P/E ratio is 96.01; Innovent Biologics is estimated to report earnings on March 31, 2027, and the estimated EPS forecast is ¥0.17. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | ¥ 13.04B | ¥ 9.42B | ¥ 6.21B | ¥ 4.56B | ¥ 4.27B |
| Gross Profit | ¥ 10.00B | ¥ 7.91B | ¥ 4.40B | ¥ 3.63B | ¥ 3.70B |
| Operating Income | ¥ 733.62M | ¥ -755.87M | ¥ -1.68B | ¥ -3.12B | ¥ -2.70B |
| EBITDA | ¥ 1.33B | ¥ -336.10M | ¥ -660.68M | ¥ -1.75B | ¥ -2.37B |
| Net Income | ¥ 813.57M | ¥ -94.63M | ¥ -1.03B | ¥ -2.18B | ¥ -2.73B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | ¥ 18.24B | ¥ 7.88B | ¥ 10.97B | ¥ 9.17B | ¥ 9.02B |
| Total Assets | ¥ 37.36B | ¥ 21.60B | ¥ 20.63B | ¥ 17.59B | ¥ 16.24B |
| Total Debt | ¥ 2.82B | ¥ 2.83B | ¥ 3.62B | ¥ 3.23B | ¥ 2.50B |
| Net Debt | ¥ -14.54B | ¥ -4.68B | ¥ -6.43B | ¥ 2.21B | ¥ 1.14B |
| Total Liabilities | ¥ 17.20B | ¥ 8.48B | ¥ 8.10B | ¥ 6.86B | ¥ 5.91B |
| Stockholders' Equity | ¥ 19.36B | ¥ 13.12B | ¥ 12.53B | ¥ 10.73B | ¥ 10.33B |
| Cash Flow | |||||
| Free Cash Flow | ¥ 9.32B | ¥ -418.39M | ¥ -1.24B | ¥ -3.30B | ¥ -3.87B |
| Operating Cash Flow | ¥ 10.00B | ¥ 1.29B | ¥ 147.81M | ¥ -1.92B | ¥ -2.02B |
| Investing Cash Flow | ¥ -6.51B | ¥ -1.17B | ¥ -998.66M | ¥ -1.44B | ¥ -2.70B |
| Financing Cash Flow | ¥ 4.73B | ¥ -606.63M | ¥ 2.59B | ¥ 2.89B | ¥ 5.00B |
Currency in CNY
